Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
1.
Journal of Leukemia & Lymphoma ; (12): 509-512, 2022.
Article in Chinese | WPRIM | ID: wpr-953993

ABSTRACT

Acute lymphoblastic leukemia (ALL) is a malignant tumor dominated by B-cell or T-cell proliferation, of which 80% is the malignant proliferation of B-lymphocytes, and it can be more commonly seen in children. Studies have found that ALL is often accompanied by abnormal molecular biological phenotypes. The study of the molecular biological characteristics of ALL helps the precise diagnosis, prognostic analysis, pathogenesis research and the discovery of new diagnostic markers and therapeutic targets. This article summarizes several molecular markers of adult acute B-lymphoblastic leukemia discovered in recent years, and reviews the clinical significance.

2.
Journal of Leukemia & Lymphoma ; (12): 484-487, 2022.
Article in Chinese | WPRIM | ID: wpr-953990

ABSTRACT

Objective:To investigate the clinical characteristics and prognosis of IL3-IGH fusion gene-positive pediatric acute lymphoblastic leukemia (ALL) with hypereosinophilia as the first presentation.Methods:The clinical data of 1 pediatric IL3-IGH fusion gene-positive ALL patient with hypereosinophilia as the first presentation in January 2021 in Fujian Medical University Union Hospital was retrospectively analyzed and relevant literature was reviewed.Results:This 11-year-old male patient underwent bone marrow examination, and results showed that the proportion of eosinophils was increased; immunophenotyping disclosed that there were about 49.4% abnormal naive B lymphocytes in bone marrow; 43 leukemia fusion genes showed all negative; the whole transcriptome sequencing showed IL3-IGH fusion gene-positive. The patient was finally diagnosed as B-ALL with IL3-IGH fusion gene. According to the Chinese Children Cancer Group (CCCG)-ALL 2020 regimen, eosinophils returned to normal after induction therapy. Bone marrow examination on day 19 of induction showed that the proportion of promyelocytes was 0.005, the proportion of eosinophils was 0.05, and the minimal residual disease (MRD) was 23.02%. Bone marrow examination on day 46 of induction showed remission, and MRD was 0.18%. Consolidation chemotherapy used CAT (cyclophosphamide 1 g/m 2 once; cytarabine 50 mg/m 2, 12 h once, 7 days in total; mercaptopurine 40 mg/m 2, once per night, 7 days in total) regimen. Then the patient was added with lusotinib (75 mg 12 h once) orally and continued to receive high-dose methotrexate (5 g/m 2) regimen chemotherapy for 2 courses, the MRD was 0.20%. Chimeric antigen receptor T-cell (CAR-T) regimen was administered, followed by negative MRD. Conclusions:IL3-IGH fusion gene ALL is more frequently found in males, and more common in older children and young adults. It is prone to organ infiltration damage, and it has a high rate of induction failure and recurrence as well as poor prognosis.

3.
Journal of Leukemia & Lymphoma ; (12): 480-483, 2022.
Article in Chinese | WPRIM | ID: wpr-953989

ABSTRACT

Objective:To investigate the molecular genetic and clinical characteristics of MEF2D-BCL9 fusion gene-positive acute B-cell lymphoblastic leukemia (B-ALL), and to provide the reference for the diagnosis and treatment of the disease.Methods:The medical record and experimental examination data of a 18-year-old female MEF2D-BCL9 fusion gene-positive B-ALL patient were retrospectively analyzed. The clinical manifestations and biological characteristics of MEF2D-BCL9 fusion gene-positive B-ALL were summarized.Results:This 18-year-old female patient was treated in a local hospital in December 2018 and was diagnosed as B-ALL. She achieved complete remission after chemotherapy and recurred at 6 months after the initial onset, and then she was admitted to Hebei Yanda Ludaopei Hospital in the 9 months after the initial onset.MEF2D-BCL9 fusion gene was detected through RNA-sequencing (RNA-seq) and verified by using polymerase chain reaction and Sanger sequencing. Bone marrow cell morphology was similar to mature B cells with vacuoles but without characteristic chromosome karyotype abnormalities. The patient achieved remission after VLD regimen chemotherapy, chimeric antigen receptor T-cell (CAR-T) therapy and bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT). She has maintained complete remission for 2 years at the last follow-up in February 2022.Conclusions:MEF2D-BCL9 fusion gene-positive B-ALL is characterized with high risk, early relapse and poor prognosis. These patients may benefit from CAR-T and allo-HSCT. It further emphasizes the importance of taking MEF2D-BCL9 fusion gene into the detection or identification by using RNA-seq, particularly for those newly diagnosed B-ALL patients in children and adolescents with specific bone marrow morphology.

4.
Rev. méd. Chile ; 149(9): 1249-1257, sept. 2021. tab, ilus, graf
Article in Spanish | LILACS | ID: biblio-1389593

ABSTRACT

Background: Before the advent of tyrosine kinase inhibitors (TKIs), patients with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ALL) had a poor prognosis. The association of TKIs to intensive chemotherapy (CT) improved outcome. Aim: To evaluate results of an intensive CT protocol including TKI in a public hospital in Santiago, Chile. Material and Methods: All patients with Ph+ALL diagnosed between January 2010 and February 2019, and who met inclusion criteria for intensive CT, received the Ph+ALL national protocol in association with imatinib and were included in this analysis. Results: Thirty-five patients aged 15 to 59 years received treatment. Complete response (CR) was obtained in 97%. Measurable residual disease (MRD) was negative in 61% (19/31 evaluable cases) during follow-up, and 55% (16/29) were MRD (-) before three months. Relapse was observed in 13 cases. Three patients underwent allogeneic hematopoietic stem cell transplant (HSCT), two in CR1. The overall survival (OS) and event-free survival (EFS) at three years were 52 and 34%, respectively. In patients who achieved MRD negativity before three months, no statistically significant differences in OS (64 and 42% respectively, p = 0.15) or EFS (35 and 32% respectively, p = 0.37) were observed. Conclusions: The prognosis of Ph+ALL improved with the association of imatinib to intensive CT. MRD-negative status before three months in this series was not significantly associated with better outcomes. Our series suggests that the Ph+ALL national protocol associated to TKI is a therapeutic alternative with high CR and aceptable MRD (-) rates.


Subject(s)
Humans , Adolescent , Adult , Middle Aged , Young Adult , Philadelphia Chromosome , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Neoplasm, Residual/diagnosis , Neoplasm, Residual/drug therapy , Protein Kinase Inhibitors/therapeutic use , Imatinib Mesylate/therapeutic use
5.
Oncología (Guayaquil) ; 30(1): 66-81, Abril. 2020.
Article in Spanish | LILACS | ID: biblio-1140886

ABSTRACT

Introducción: La leucemia linfoblásticaaguda (LLA) es una de las oncopatologías más frecuentes a nivel infantil, ocupando el primer lugar de los cincos tipos de cáncer con mayor incidencia en Ecuador. El objetivodel estudio fue determinar las frecuencias genotípicas y alélicas delos polimorfismos genéticos de MTHFR 677C>T (rs1801133) y MTHFR 1298A>C(rs1801131) en niños con leucemia linfoblástica aguda de SOLCA ­Loja y SOLCA ­Cuenca. Métodos:Es un estudio transversal, donde se evaluó a 160 pacientes pediátricosdiagnosticados con LLA. La detección de lospolimorfismos MTHFR 677C>T y 1298A>C se realizó mediante la técnica PCR entiempo real. El análisis estadístico descriptivo se desarrolló a través del software IBM SPSS (versión 22) y el programa bioinformático SNPStats. Resultados: Se determinóque las frecuencias genotípicas para el SNP MTHFR 677C>T fueron 25% C/C y 75%C/T con una frecuencia alélica del 38% para el alelo mutado (T). Para el SNP MTHFR1298 A>C se encontró una frecuencia genotípica de 2% A/A, 16% A/C y 82% C/C, entanto que su frecuencia alélica fue del 90% para el alelo mutado (C). No se encontróasociación genotípica ni alélica con ninguna de las variables intervinientes (p>0.05),así como tampoco se manifestó una correlación estadísticamente significativa de lospolimorfismos en mención y el tipo de riesgo de LLA. Conclusión:En la población estudiada con LLA, se evidenció para el SNP de MTHFR 677C>T una frecuencia genotípica del 75% para el heterocigoto C/T. Para el SNP MTHFR 1298A>C se encontró una frecuencia genotípica del 82% para el homocigoto mutado C/C. La distribución de la frecuencia alélica se mostró de la siguiente manera: para MTHFR 677C>T se obtuvo 38% para el alelo mutado T y en cuanto a MTHFR 1298 A>C, 90% correspondió para el alelo mutado C. En el análisis estadístico no se encontró asociación genotípica ni alélica con las variablesdemográficas y clínicas


Introduction:Acute lymphoblastic leukemia (ALL) is one of the most frequent oncopathologiesin childhood, occupying the first place of the five types of cancer with the highest incidence in Ecuador. The objective of the study was to determine the genotypic and allelic frequencies of the genetic polymorphisms of MTHFR 677C> T (rs1801133) and MTHFR 1298A> C (rs1801131) in children with acute lymphoblastic leukemia from SOLCA -Loja and SOLCA -Cuenca. Methods: It is a cross-sectional study, where 160 pediatric patients diagnosed with ALL were evaluated. The detection of MTHFR 677C> T and 1298A> C polymorphisms was performed using the real-time PCR technique. The descriptive statistical analysis was developed using the IBM SPSS software (version 22) and the SNPStats bioinformatics program. Results: It was determined that the genotype frequencies for the SNP MTHFR 677C> T were 25% C / C and 75% C / T with an allele frequency of 38% for the mutated allele (T). For the SNP MTHFR 1298 A> C, a genotype frequency of 2% A / A, 16% A / C and 82% C / C was found, while its allelic frequency was 90% for the mutated allele (C). No genotypic or allelic association was found with any of the intervening variables (p> 0.05), as well as no statistically significant correlation of the mentioned polymorphisms and the type of risk of ALL. Conclusion: In the population studied with ALL, a genotypic frequency of 75% was evidenced for the MTHFR 677C> T SNP for the heterozygous C / T. For the SNP MTHFR 1298A> C, a genotypic frequency of 82% was found for the homozygous mutated C / C. The allelic frequency distribution was shown as follows: for MTHFR 677C> T, 38% was obtained for the mutated allele T and for MTHFR 1298 A> C, 90% corresponded to the mutated allele C. In the statistical analysis No genotypic or allelic association was found with demographic and clinical variables


Subject(s)
Humans , Polymorphism, Genetic , Leukemia, Biphenotypic, Acute , Precursor Cell Lymphoblastic Leukemia-Lymphoma
6.
Arq. neuropsiquiatr ; 78(2): 63-69, Feb. 2020. tab
Article in English | LILACS | ID: biblio-1089001

ABSTRACT

Abstract Objective: Investigate the auditory pathway in the brainstem of children with acute lymphoblastic leukemia submitted to chemotherapy (by intravenous or intrathecal infusion). Methods: Fourteen children aged between 2 and 12 years with diagnosis of acute lymphoid leukemia were evaluated. The following procedures were used: meatoscopy, acoustic immitance measurements, tonal audiometry, vocal audiometry, transient otoacoustic emissions, and auditory brainstem response. Results: From the 14 children with normal auditory thresholds, 35.71% showed an alteration in auditory brainstem response, with a predominance of hearing impairment in the lower brainstem. It was found that 80% of the children with alteration had used intrathecal methotrexate less than 30 days and that 40% had the highest cumulative intravenous methotrexate doses. Conclusion: Children with acute lymphoblastic leukemia submitted to chemotherapy, present auditory pathway impairment in the brainstem, with a predominance of a low brainstem.


Resumo Objetivo: Investigar a via auditiva em tronco encefálico de crianças com leucemia linfoide aguda submetidas à quimioterapia (por infusão intravenosa ou por via intratecal). Métodos: Foram avaliadas 14 crianças com idade entre 2 e 12 anos, com diagnóstico de leucemia linfoide aguda. Foram utilizados os seguintes procedimentos: meatoscopia, medidas de imitância acústica, audiometria tonal, audiometria vocal, emissões otoacústicas transientes e potencial evocado auditivo de tronco encefálico. Resultados: Das 14 crianças com limiares auditivos normais, 35,71% demonstraram alteração no Potencial Evocado Auditivo de Tronco Encefálico, com predomínio de comprometimento de via auditiva em tronco encefálico baixo. Verificou-se que 80% das crianças com alteração haviam feito uso do metotrexato via intratecal a menos de 30 dias e que 40% tinham as maiores doses acumulativas de metotrexato por via endovenosa. Conclusão: Crianças com leucemia linfoide aguda submetidas à quimioterapia apresentam comprometimento na via auditiva em tronco encefálico, com predomínio em tronco encefálico baixo.


Subject(s)
Humans , Child, Preschool , Child , Otoacoustic Emissions, Spontaneous , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Auditory Pathways , Auditory Threshold , Brain Stem , Methotrexate , Evoked Potentials, Auditory, Brain Stem
7.
Ciênc. cuid. saúde ; 19: e50017, 20200000. graf
Article in Portuguese | LILACS, BDENF | ID: biblio-1356100

ABSTRACT

RESUMO Introdução: A Leucemia Linfocítica Aguda (LLA) é um tipo de câncer que acomete o processo hematopoiético e está diretamente relacionada a fatores genéticos e ambientais. Objetivo: Identificar na literatura a existência de associação entre a exposição à agrotóxicos e o desenvolvimento de Leucemia Linfocítica Aguda em crianças no cenário nacional e internacional. Métodos: Realizou-se uma revisão de escopo nas bases de dados LILACS, IBECS, MEDLINE, BDENF, CINAHL e bibliotecas Cochrane e Scielo e Google Scholar. Incluíram-se produções relacionadas à exposição por agrotóxicos e o desenvolvimento de Leucemia Linfocítica Aguda em crianças. Resultados: A revisão abrangeu 22 estudos publicados de 2008 a 2017. A associação da exposição a pesticidas com o desenvolvimento de LLA infantil deu-se na exposição materna aos pesticidas domésticos no período pré-concepção, gestacional e exposição da própria criança à pesticidas domésticos na primeira infância. Conclusão: Os resultados permitiram identificar as publicações sobre a associação entre o uso de agrotóxicos e o desenvolvimento de Leucemia Linfocítica Aguda em crianças. Entretanto, há a necessidade de novos estudos sobre a exposição de crianças à pesticidas domésticos, conhecimento sobre sua toxicidade e danos à saúde humana, assim como medidas para redução do uso.


RESUMEN Introducción: la Leucemia Linfocítica Aguda (LLA) es un tipo de cáncer que acomete el proceso hematopoyético y está directamente relacionada a factores genéticos y ambientales. Objetivo: identificar en la literatura la existencia de asociación entre la exposición a pesticidas y el desarrollo de Leucemia Linfocítica Aguda en niños ene les cenario nacional e internacional. Métodos: se realizó una revisión del alcance en las bases de datos LILACS, IBECS, MEDLINE, BDENF, CINAHL y bibliotecas Cochrane y Scielo y Google Scholar. Se incluyeron producciones relacionadas a la exposición por pesticidas yel desarrollo de Leucemia Linfocítica Aguda en niños. Resultados: la revisión abarcó 22 estudios publicados de 2008 a 2017. La asociación de la exposición a pesticidas con el desarrollo de LLA infantil ocurrióen la exposición materna a los pesticidas domésticos en el período preconcepción, gestacional y exposición del proprioniño a pesticidas domésticos en la primera infancia. Conclusión: los resultados permitieron identificar las publicaciones sobre la asociación entre el uso de pesticidas y el desarrollo de Leucemia Linfocítica Aguda en niños. Pero, hay la necesidad de nuevos estudios sobre la exposición de niños a pesticidas domésticos, conocimiento sobre su toxicidad ylos daños a la salud humana, así como medidas para la reducción del uso.


ABSTRACT Introduction: Acute Lymphocytic Leukemia (ALL) is a type of cancer that affects the hematopoietic process and is directly related to genetic and environmental factors. Objective: To identify in the literature the existence of an association between exposure to pesticides and the development of Acute Lymphocytic Leukemia in children in the national and international scenario. Methods: A scoping review was carried out in the LILACS, IBECS, MEDLINE, BDENF, CINAHL databases, and Cochrane and Scielo and Google Scholar libraries. Production related to pesticide exposure and the development of Acute Lymphocytic Leukemia in children were included. Results: The review had 22 studies published from 2008 to 2017. The association of pesticide exposure with the development of childhood ALL was due to maternal exposure to domestic pesticides in the pre-conception, gestational period, and the child's exposure to domestic pesticides in early childhood. Conclusion: The results allowed us to identify publications on the association between the use of pesticides and the development of Acute Lymphocytic Leukemia in children. However, there is a need for further studies on children's exposure to domestic pesticides, knowledge of their toxicity, and damage to human health, as well as measures to reduce its use.


Subject(s)
Humans , Male , Female , Child , Child Development/drug effects , Agrochemicals/poisoning , Precursor Cell Lymphoblastic Leukemia-Lymphoma/prevention & control , Child Health , Pesticide Exposure , Environment , Toxicity/policies
8.
J. Bras. Patol. Med. Lab. (Online) ; 56: e2092020, 2020. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1134628

ABSTRACT

ABSTRACT Rare clinical case of acute lymphocytic leukemia (ALL) associated with toxoplasmosis affecting a 23-year-old male patient with progressive dyspnea. Chest computed tomography revealed expansive lesions indicating right supraclavicular fossa lymph node enlargement and right pleural effusion. Toxoplasmosis serology was performed: positive for immunoglobulin G [(IgG) 180.6] and positive for immunoglobulin M [(IgM) 0.98]. Therefore, treatment for the infection was initiated and immunohistochemistry of left cervical lymph node revealed ALL. Consequently, chemotherapy treatment was introduced at an oncology center. The diagnosis of toxoplasmosis allowed treatment to be administered, preventing the worsening of the condition caused by chemotherapy-induced immunosuppression.


RESUMEN Reportamos un caso clínico raro de leucemia linfocítica aguda (LLA) asociada a toxoplasmosis en un paciente masculino de 23 años con cuadro de disnea progresiva. La tomografía de tórax reveló lesiones expansivas, indicando agrandamiento de los ganglios linfáticos en fosa supraclavicular derecha y derrame pleural a la derecha. Examen serológico para toxoplasmosis: inmunoglobulinas G (IgG) e inmunoglobulinas M (IgM) positivas - 180,6 y 0,98, respectivamente. Se inició el tratamiento de la infección; la inmunohistoquímica de ganglio linfático cervical izquierdo reveló LLA. Se llevó a cabo la quimioterapia en un hospital oncológico. El diagnóstico de toxoplasmosis permitió hacer el tratamiento, impidiendo que la inmunosupresión inducida por la quimioterapia agravara el cuadro clínico.


RESUMO Relatamos um caso clínico raro de leucemia linfoblástica aguda (LLA) associada à toxoplasmose em um paciente do sexo masculino, 23 anos, com quadro de dispneia progressiva. A tomografia de tórax revelou lesões expansivas, indicando linfonodomegalias em fossa supraclavicular direita e derrame pleural à direita. Sorologia realizada para toxoplasmose: imunoglobulinas da classe G (IgG) e da classe M (IgM) positivas - 180,6 e 0,98, respectivamente. Tratamento para a infecção foi iniciado; estudo imuno-histoquímico de linfonodo cervical esquerdo foi realizado, revelando LLA. Institui-se tratamento quimioterápico em centro oncológico. O diagnóstico de toxoplasmose permitiu que o tratamento fosse feito, impedindo que a imunossupressão induzida pela quimioterapia agravasse o quadro clínico.

9.
Journal of Breast Cancer ; : 100-106, 2020.
Article in English | WPRIM | ID: wpr-811192

ABSTRACT

Palbociclib, in conjunction with endocrine therapy, has been approved for the treatment of patients with advanced breast cancer. The common hematological toxicities associated with palbociclib are leukopenia and neutropenia. However, hematological malignancies have not been reported for palbociclib treatment. Here, for the first time, we present a case of acute lymphoblastic leukemia that was diagnosed in a patient undergoing treatment with letrozole and palbociclib for metastatic breast cancer. This case emphasizes the need for long term follow up of patients treated with palbociclib.


Subject(s)
Humans , Breast Neoplasms , Follow-Up Studies , Hematologic Neoplasms , Leukopenia , Neutropenia , Precursor Cell Lymphoblastic Leukemia-Lymphoma
10.
Chinese Journal of Pathology ; (12): 149-155, 2020.
Article in Chinese | WPRIM | ID: wpr-799500

ABSTRACT

Objective@#To investigate the clinicopathological features, immunophenotypes, genetics and prognosis of T-lymphocyte lymphoma/myeloid sarcoma combined with Langerhans cell histiocytyosis (coexistence of T-LBL/MS and LCH).@*Methods@#Clinical and pathological data of the 6 patients with coexistence of T-LBL/MS and LCH were analyzed, who were diagnosed at the Foshan Hospital of Sun Yat-sen University and the Friendship Hospital of Capital Medical University, from December 2013 to April 2019. The hematoxylin and eosin stain, immunohitochemistry (EnVision) and in situ hybridization were used. Related literatures were reviewed.@*Results@#Four patients were T-LBL combined with LCH, 1 was T-LBL/MS combined with LCH, and 1 was MS combined with LCH. There were 2 male and 4 female patients, with age ranged from 5 to 77 years old (median, 59 years old). Three patients represented with only multiple lymph node swelling. The other 3 displayed both multiple lymph node swelling, and skin/liver or spleen lesions. Lymph node structure was destroyed in 5 cases, while 3 cases had several residual atrophic follicles. Histologically, there were two types of tumor cells: one type of the abnormal lymphoid-cells exhibited small to medium-sized blast cells, typically showing a nested distribution, and these cells were mainly identified in residual follicles and paracortical areas; the other type of histiocytoid cells had a large cell size and abundant pale or dichromatic cytoplasm. Their nuclei were irregularly shaped, showing folded appearance and nuclear grooves. These cells were mainly present in marginal sinus, medullary sinus and interstitial area between follicles. Eosinophil infiltration in the background was not evident in any of the cases. The lymphoid-cells of medium size showed TdT+/CD99+/CD7+, with variable expression of CD34/MPO/CD2/CD3. Ki-67 index was mostly 30%-50%. However, the histiocytoid cells showed phenotype of CD1a+/S-100+/Langerin+/-, while CD163/CD68 were positive in some degree. These cells did not express any T or B cell markers. The Ki-67 index mostly ranged between 10%-20%. None of the cases had Epstin-Barr viral infection. Among the 6 patients, 4 patients were followed up (6-63 months, median time, 18.5 months), of whom 1 patient died of the disease and 3 patients were alive at the end of follow-up.@*Conclusions@#T-LBL/MS combined with LCH is a rare mixed type of immature hematopoietic disease, and mainly occurs in lymph node and skin. The clinical course is overall aggressive. Therefore, it is helpful to recognize and identify the two pathologic components in the same tissue for accurate diagnosis and proper treatment.

11.
Chinese Journal of Pathology ; (12): 149-155, 2020.
Article in Chinese | WPRIM | ID: wpr-787653

ABSTRACT

To investigate the clinicopathological features, immunophenotypes, genetics and prognosis of T-lymphocyte lymphoma/myeloid sarcoma combined with Langerhans cell histiocytyosis (coexistence of T-LBL/MS and LCH). Clinical and pathological data of the 6 patients with coexistence of T-LBL/MS and LCH were analyzed, who were diagnosed at the Foshan Hospital of Sun Yat-sen University and the Friendship Hospital of Capital Medical University, from December 2013 to April 2019. The hematoxylin and eosin stain, immunohitochemistry (EnVision) and in situ hybridization were used. Related literatures were reviewed. Four patients were T-LBL combined with LCH, 1 was T-LBL/MS combined with LCH, and 1 was MS combined with LCH. There were 2 male and 4 female patients, with age ranged from 5 to 77 years old (median, 59 years old). Three patients represented with only multiple lymph node swelling. The other 3 displayed both multiple lymph node swelling, and skin/liver or spleen lesions. Lymph node structure was destroyed in 5 cases, while 3 cases had several residual atrophic follicles. Histologically, there were two types of tumor cells: one type of the abnormal lymphoid-cells exhibited small to medium-sized blast cells, typically showing a nested distribution, and these cells were mainly identified in residual follicles and paracortical areas; the other type of histiocytoid cells had a large cell size and abundant pale or dichromatic cytoplasm. Their nuclei were irregularly shaped, showing folded appearance and nuclear grooves. These cells were mainly present in marginal sinus, medullary sinus and interstitial area between follicles. Eosinophil infiltration in the background was not evident in any of the cases. The lymphoid-cells of medium size showed TdT+/CD99+/CD7+, with variable expression of CD34/MPO/CD2/CD3. Ki-67 index was mostly 30%-50%. However, the histiocytoid cells showed phenotype of CD1a+/S-100+/Langerin+/-, while CD163/CD68 were positive in some degree. These cells did not express any T or B cell markers. The Ki-67 index mostly ranged between 10%-20%. None of the cases had Epstin-Barr viral infection. Among the 6 patients, 4 patients were followed up (6-63 months, median time, 18.5 months), of whom 1 patient died of the disease and 3 patients were alive at the end of follow-up. T-LBL/MS combined with LCH is a rare mixed type of immature hematopoietic disease, and mainly occurs in lymph node and skin. The clinical course is overall aggressive. Therefore, it is helpful to recognize and identify the two pathologic components in the same tissue for accurate diagnosis and proper treatment.

12.
RGO (Porto Alegre) ; 67: e20190018, 2019. tab
Article in English | LILACS-Express | LILACS | ID: biblio-1002977

ABSTRACT

ABSTRACT Objective: The aim of this study was to evaluate the prevalence of Candida colonizationon oral cavity of pediatric individuals with acute lymphocytic leukemia (ALL) and its susceptibility/resistance to nystatin and amphotericin B. Methods: This was a cross sectional study with observational, descriptive and analytic approach. Saliva was collected from40 individuals diagnosed with ALL and from40 healthy subjects, as a comparative group, matched by age and gender with ALL group. The mean age for both groups were 8 years-old. The isolation and identification of the Candidaspecies were performed using the CHROMagarCandidaTM and confirmed by polymerase chain reaction. The samples were subjected to antifungal susceptibility by microdilution assay for nystatin and amphotericin B. Salivary alterations and chemotherapy-induced oralmucositis were evaluated using modifiedOral Assessment Guide. Results: The positivity to Candida was higher inALL individuals (32.5%,13/40)than in a comparative group(2.5%, 1/40) (p<0.001). Candida albicans was the most prevalent strain (86.6%). The mucositis was directly associated with positive Candidacolonization (p=0.017) in the ALL group but not related with salivary alterations (p= 0.479). Six strains of C. albicans (54.5%), on ALL group, were resistant to nystatin and all strains were not susceptible to amphotericin B. Conclusion: Candida colonization was associated with ALL condition and with oral mucositis in these individuals. C. albicans was the prevalent strain and most samples were resistant to antifungal agents tested, nystatin and amphotericin B.


RESUMO Objetivo: o objetivo deste estudo foi avaliar a prevalência e colonização de Candida na cavidade oral de indivíduos pediátricos com leucemia linfocítica aguda (LLA) e sua susceptibilidade/resistência à nistatina e à anfotericina B. Métodos: estudo transversal observacional com abordagem descritiva e analítica. A saliva foi coletada de 40 indivíduos diagnosticados com LLA e de 40 indivíduos saudáveis, como grupo comparativo, combinados por idade e sexo com o grupo LLA. A idade média para ambos os grupos foi de 8 anos de idade. O isolamento e a identificação das espécies de Candida foram realizados utilizando o CHROMagarCandidaTM e confirmados pela reação em cadeia da polimerase. As amostras foram submetidas a susceptibilidade antifúngica por meio de ensaio de microdiluição para nistatina e anfotericina B. As alterações salivares e a mucosite oral induzida por quimioterapia foram avaliadas utilizando o Guia de avaliação modificada. Resultados: A positividade para Candida foi superior aos indivíduos in situ (32,5%, 13/40) do que em um grupo comparativo (2,5%, 1/40) (p <0,001). Candida albicans foi a cepa mais prevalente (86,6%). A mucosite foi diretamente associada à colonização positive por Candida (p = 0,017) no grupo LLA, mas não relacionada com alterações salivares (p = 0,479). Seis estirpes de C. albicans (54,5%), no grupo LLA, eram resistentes à nistatina e todas as cepas não eram suscetíveis à anfotericina B. Conclusão: A colonização por Candida foi associada à condição LLA e à mucosite oral nesses indivíduos. C. albicans era a cepa predominante e a maioria das amostras eram resistentes aos agentes antifúngicos testados, nistatina e anfotericina B.

13.
Journal of Chinese Physician ; (12): 1592-1595, 2019.
Article in Chinese | WPRIM | ID: wpr-797093

ABSTRACT

Acute lymphoblastic leukemia (ALL) is a highly heterogeneous disease. The prognosis of adolescents and adults with ALL is worse than that of children with ALL, mainly because of differences in biological characteristics. Molecular markers are of great value on risk stratification, prognosis evaluation, treatment guidance. The good news is with the deepening of studies on pathogenesis of ALL and the introduction of new technologies, novel molecular markers of prognostic relevance continue to be discovered. It was found that increased Sox4 expression was shown to correlate with accelerate leukemia progression. Unfortunately, resistance to medicine is associated with two cyclin-dependent kinase-inhibitor-2AB (CDKN2A/B) deletion.And the deletion of IKZF1 increase risk of relapse. Meanwhile, Ph-like acute lymphoblastic leukemia is characterized by a variety of genetic alterations that activate kinase or cytokine receptor signaling pathway. Identification of these molecular markers will provide important insights into the treatment strategies. This paper reviewed the advance in the Ph-positive ALL and Ph-like ALL.

14.
Journal of Chinese Physician ; (12): 1592-1595, 2019.
Article in Chinese | WPRIM | ID: wpr-791180

ABSTRACT

Acute lymphoblastic leukemia (ALL) is a highly heterogeneous disease.The prognosis of adolescents and adults with ALL is worse than that of children with ALL,mainly because of differences in biological characteristics.Molecular markers are of great value on risk stratification,prognosis evaluation,treatment guidance.The good news is with the deepening of studies on pathogenesis of ALL and the introduction of new technologies,novel molecular markers of prognostic relevance continue to be discovered.It was found that increased Sox4 expression was shown to correlate with accelerate leukemia progression.Unfortunately,resistance to medicine is associated with two cyclin-dependent kinase-inhibitor-2AB (CDKN2A/B) deletion.And the deletion of IKZF1 increase risk of relapse.Meanwhile,Ph-like acute lymphoblastic leukemia is characterized by a variety of genetic alterations that activate kinase or cytokine receptor signaling pathway.Identification of these molecular markers will provide important insights into the treatment strategies.This paper reviewed the advance in the Ph-positive ALL and Ph-like ALL.

15.
Rev. méd. Chile ; 146(7): 846-853, jul. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-961470

ABSTRACT

Background: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest. Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse. Material and Methods. We included 123 patients treated with metformin and without metformin. The dose used was 850 mg PO at 8 h intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test. Results. The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p = 0.006). Conclusions. The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Metformin/therapeutic use , Recurrence , Acute Disease , Survival Rate , Risk Factors , Apoptosis , Disease-Free Survival
16.
Chinese Journal of Pathology ; (12): 119-122, 2018.
Article in Chinese | WPRIM | ID: wpr-809843

ABSTRACT

Objective@#To evaluate the expression of βF1 and T cell receptor (TCR)γ in T lymphoblastic lymphoma/leukemia(T-LBL/ALL), and investigate the clinicopathological features.@*Methods@#Fifty-one cases of T-LBL/ALL were collected at Guangdong General Hospital from 2010 to 2016, the expression of βF1 and TCRγ was assessed by immunohistochemistry.@*Results@#There were 13 cases of children and adolescents, and 38 cases of adults. The expression rates of βF1 and TCRγ were 27.5%(14/51) and 15.7%(8/51) respectively. The proportion of adults in αβ T-LBL/ALL, TCR-silent T-LBL/ALL and γδ T-LBL/ALL was 7/14, 79.3%(23/29)and 8/8 respectively, and the difference was significant (P=0.023). There was no statistical difference in sex, LDH, bone marrow involvement and Ann arbor stage among these three groups(P>0.05). γδ T-LBL/ALLs included 6 cases of CD4-/CD8- phenotype, whereas αβ T-LBL/ALL included 7 cases of CD4+ /CD8+ phenotype. There was significant difference in CD4/CD8 expression among these three groups(P<0.01).@*Conclusions@#γδ T-LBL/ALL occurred only in adults, with predominantly CD4-/CD8- phenotype. αβ T-LBL/ALL occurred more common in children and adolescents, with predominantly CD4+ /CD8+ phenotype.

17.
Chinese Journal of Medical Imaging Technology ; (12): 136-139, 2018.
Article in Chinese | WPRIM | ID: wpr-706194

ABSTRACT

Acute lymphoblastic leukemia is the most common malignant tumor of children.Due to the application of individual chemotherapy,the cure rate of this disease is increasing.Because of the rapid development of brain in childhood,the chemotherapeutic drugs can affect the neurocognitive function of children in varying degrees.The progresses of pathophysiology,neurological function,MRI of acute lymphoblastic leukemia related neurocognitive impairment were reviewed in this article.

18.
Chongqing Medicine ; (36): 311-315, 2018.
Article in Chinese | WPRIM | ID: wpr-691788

ABSTRACT

Objective To investigate the clinical features,treatment regimen and prognosis of acute lymphoblastie leukemia (ALL) complicating central nervous system leukemia (CNSL).Methods The clinical data,results of laboratory detection and imageological examination in the patients with ALL complicating CNSL in this hospital from January 2005 to January 2015 were retrospectively analyzed.Results A total of 83 cases were collected,including 52 male cases(62.65%) and 31 female cases (37.35%) with a median age of 27 (15-72) years old.Among them,19 cases were T cells ALL(T-ALL),54 eases were B cell ALL(B-ALL),3 cases were Burkitt lymphoma/leukemia,2 cases were ALL (T/B lymphocyte) and 5 cases were undefined type.The median follow-up time was 10(1-52) months.The univariate analysis results showed that the patients with high WBC count (WBC≥100× 109) at initial diagnosis or unreach complete remission (CR) after 1 treatment course had relatively poor prognosis.Receiving the radiotherapy could improve the patients' survival rate(P<0.05).In the multivariate analysis,high WBC count at initial diagnosis was an independent prognostic factor affecting the patients' overall survival(OS) (P=0.007).Conclusion The clinical features in the patients' with ALL complicating CNSL have poor specificity,high WBC level and unreaching CR by 1 treatment course are the poor prognosis factors,and local radiotherapy has a certain significance for prolonging the patients' survival period.

19.
Blood Research ; : 53-60, 2018.
Article in English | WPRIM | ID: wpr-713628

ABSTRACT

BACKGROUND: The numerous side effects and chemo-resistance of conventional chemical drugs in the treatment of malignancies have led to consideration of the anti-cancer properties of natural products. In the present study, we aimed to explore the apoptotic effect of two natural components, resveratrol and prednisolone, on the T acute lymphoblastic leukemia (ALL) cell line, CCRF-CEM. Our findings suggested the incorporation of these natural agents into drug regimens to treat patients with ALL. METHODS: In this study, we investigated the effect of different doses of resveratrol (15, 50 and 100 µM) and prednisolone (700 µM) on BAX (apoptosis promoter) and BCL2 (apoptosis inhibitor) expressions following 24 and 48 hours of treatment on CCRF-CEM cells, using real-time PCR, and on apoptosis induction using flow cytometry. RESULTS: The results showed a time- and dose-dependent increase in BAX expression and a decrease in BCL2 expression. Apoptosis was induced in CCRF-CEM cells treated with resveratrol and prednisolone for 24 and 48 hours. Combined resveratrol and prednisolone treatment showed synergistic effects on the overexpression of BAX and the downregulation of BCL2. The drug combination had a greater influence on apoptosis induction compared with either drug administered alone after 48 hours of treatment. CONCLUSION: The results of this study suggested that resveratrol exhibited a remarkable efficacy to improve the influence of glucocorticoids drugs, especially prednisolone, to induce apoptosis in the CCRF-CEM cell line.


Subject(s)
Humans , Apoptosis , Biological Products , Cell Line , Down-Regulation , Flow Cytometry , Glucocorticoids , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma , Prednisolone , Real-Time Polymerase Chain Reaction
20.
Blood Research ; : 138-144, 2018.
Article in English | WPRIM | ID: wpr-714930

ABSTRACT

BACKGROUND: Targeted therapy has revolutionized the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapse still occurs because of the presence of quiescent stem cells, termed leukemia propagating cells (LPCs). This study aimed to assess the phenotypic diversity of LPCs in adult patients with Ph+ B-Acute ALL (B-ALL) and to assess its prognostic impact. METHODS: Seventy adults with newly diagnosed Ph+ B-ALL were recruited at the Mansoura Oncology Center. Multiparameter flow cytometry studies of mononuclear blast cells for cluster of differentiation (CD)34, CD38, and CD58 were performed. RESULTS: Seventeen patients had blasts with the pattern of LPCs (CD34+CD38−CD58−), while 53 cases had other diverse phenotypic patterns. The rate of complete response was significantly lower in patients with the LPC phenotype (47% vs. 81%, P=0.006). The median time to achieve a complete response was prolonged in patients with the CD34+CD38−CD58− phenotype (48 vs. 32 days, P=0.016). The three-year overall survival was significantly lower in patients with the CD34+CD38−CD58− phenotype (37% vs. 55% respectively, P=0.028). Multivariate analysis showed that the CD34+CD38− CD58− phenotype was an independent risk factor for overall survival. CONCLUSION: The presence of CD34+CD38−CD58− LPCs at diagnosis allows rapid identification of higher risk patients. Risk stratification of these patients is needed to further guide therapy and develop effective LPCs-targeted therapy to improve treatment outcome.


Subject(s)
Adult , Humans , Diagnosis , Flow Cytometry , Leukemia , Multipotent Stem Cells , Multivariate Analysis , Phenotype , Philadelphia Chromosome , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Prognosis , Recurrence , Risk Factors , Stem Cells , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL